Regulatory News
Tuesday, January 17, 2017
BRIEF-Pluristem receives clearance from Germany to initiate its Phase III trial
* Pluristem receives clearance from germany to initiate its
multinational Phase III trial in critical limb ischemia
targeting early conditional marketing approval
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment